This week in drug discovery (25-29 April)  

News round-up by DDW’s Reece Armstrong for 25-29 April    

Q1 earnings, formulations to tackle blindness, liver cancer therapies and opportunities for malaria treatments are some of the themes of this week’s news round-up. 

What’s behind GSK’s strong Q1 earnings? 

DDW Deputy Editor Reece Armstrong looks at the key points of GSK’s first quarter earnings. UK pharmaceutical company GSK has reported strong financial earnings for the first quarter of 2022.  The pharma giant reported total sales in Q1 of £9.8 billion, crediting much of that to the company’s biopharma offerings. 

AstraZeneca’s liver cancer therapy gets accepted for review 

AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, the company has announced. 

World Malaria Day – efforts by the pharma industry 

For World Malaria Day DDW looks at some of the latest advancements from the pharmaceutical industry which are helping combat Malaria. 

 Onyx Scientific expands API offering 

Contract development and manufacturing organisation (CDMO) Onyx Scientific has opened a second facility in North East England, expanding its offerings.   

New spinout to tackle blindness with novel gel 

A new spinout has launched from the University of Birmingham targeting treatments for the leading causes of preventable blindness.  

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free